Here's the press release: http://www.prnewswire.com/news-releases/astrazeneca-announces-agreements-in-principle-in-seroquel-product-liability-litigation-100242379.html
The group said it continues to participate in the mediation process over claims in both federal and state jurisdictions. It also said that, as of June 29, approximately 2,900 additional claims have been dismissed by order or agreement.
The company said its core earnings per share guidance for 2010 remains unchanged at a range of $6.35 to $6.65.
The claims relate to allegations the company improperly promoted the drug, which is approved to treat schizophrenia, bipolar disorder and depression.